Targeted testing for viral hepatitis: Europe’s persistent public health challenge
Targeted testing is an essential element of any strategy to eliminate viral hepatitis across the countries in the European Union and European Economic Area. Some preliminary monitoring results on the response to hepatitis B and C presented around World Hepatitis Day show that diagnosing chronic infections is still a challenge in the EU/EEA.
Hepatitis B - Annual Epidemiological Report for 2017
In 2017, 30 EU/EEA Member States reported 26 907 cases of hepatitis B virus (HBV) infection. Excluding the five countries that only reported acute cases, the number of cases, 26 262, corresponds to a crude rate of 6.7 cases per 100 000 population.
Chronic hepatitis B infections on the rise since 2008
In 2017, the majority (58%) of the almost 27 000 newly reported hepatitis B cases in the European Union and European Economic Area were classified as chronic infections. This follows a consistent upward trend in reported chronic hepatitis B cases since 2008.
It is always time to test: Spring European Testing Week
In order to maximise the benefits of treatment for HIV or viral hepatitis, it is critical to test and diagnose people as soon as possible in the course of the infection. ECDC supports this objective of European Testing Week.
Hepatitis B and C testing strategies in healthcare and community settings in the EU/EEA
The scope of this project was to provide an overview of different effective testing strategies for hepatitis B and C and their outcomes in the EU/EEA, covering all relevant population groups and settings.
Surveillance systems overview for 2017
- Chikungunya virus disease
- Chlamydia infection
- Crimean-Congo haemorrhagic fever
- Ebola haemorrhagic fever
- Hantavirus infection
- Healthcare-associated infections
- Hepatitis A
- Hepatitis B
- Hepatitis C
- HIV infection
- Invasive Haemophilus influenzae disease
- Lassa fever
- Marburg haemorrhagic fever
- Meningococcal disease
- Pneumococcal disease
- Q fever
- Rift Valley fever
- Severe acute respiratory syndrome (SARS)
- Surgical site infections
- Verotoxigenic Escherichia coli infection
- West Nile virus infection
- Yellow fever
Public health guidance in brief on HIV, hepatitis B and C testing in the EU/EEA
The ECDC guidance on integrated testing of hepatitis B (HBV), hepatitis C (HCV) and HIV supports countries in the global effort to combat viral hepatitis and eliminate HIV as public health threats by 2030. At present, reaching and testing those at risk of infection with HIV, HBV or HCV is still a public health challenge across Europe. This Guidance in brief is based on the comprehensive guidance document which provides the evidence base for this guidance
Public health guidance on HIV, hepatitis B and C testing in the EU/EEA
This guidance aims to provide EU/EEA countries with an evidence-based framework to help develop, implement, monitor and evaluate their own national HBV, HCV and HIV testing guidelines and programmes.
Marking European Testing Week: ECDC issues integrated hepatitis and HIV testing Guidance
To mark European Testing Week from 23 to 30 November 2018, ECDC publishes its new Guidance on integrated viral hepatitis and HIV testing.